{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T18:23:42Z","timestamp":1787855022529,"version":"build-2784847793"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-026-06742-1","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T17:54:32Z","timestamp":1787853272000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["ctDNA-guided or ctDNA-stratified adjuvant immunotherapy compared with observation or placebo after radical surgery for muscle-invasive urothelial carcinoma: a GRADE-assessed systematic review and meta-analysis"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9811-7754","authenticated-orcid":false,"given":"Wajahat","family":"Mirza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeel","family":"Anwaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Faizan","family":"Sajid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wajiha","family":"Irfan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rao Nouman","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"issue":"22","key":"6742_CR1","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","volume":"384","author":"DF Bajorin","year":"2021","unstructured":"Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, Bamias A, Lebret T, Shariat SF, Park SH, Ye D (2021) Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med 384(22):2102\u20132114","journal-title":"N Engl J Med"},{"issue":"4","key":"6742_CR2","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","volume":"22","author":"J Bellmunt","year":"2021","unstructured":"Bellmunt J, Hussain M, Gschwend JE, Albers P, Oudard S, Castellano D, Daneshmand S, Nishiyama H, Majchrowicz M, Degaonkar V, Shi Y (2021) Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 22(4):525\u2013537","journal-title":"Lancet Oncol"},{"key":"6742_CR3","doi-asserted-by":"crossref","unstructured":"Galsky MD, Gschwend JE, Milowsky MI, Schenker M, Valderrama BP, Tomita Y, Bamias A, Lebret T, Shariat SF, Park SH, Agerbaek M (2025) Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274. Ann Oncol. Oct 17","DOI":"10.1016\/j.annonc.2025.08.3682"},{"issue":"2","key":"6742_CR4","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.eururo.2023.06.007","volume":"85","author":"T Powles","year":"2024","unstructured":"Powles T, Assaf ZJ, Degaonkar V, Grivas P, Hussain M, Oudard S, Gschwend JE, Albers P, Castellano D, Nishiyama H, Daneshmand S (2024) Updated overall survival by circulating tumor DNA status from the phase 3 IMvigor010 trial: adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma. Eur Urol 85(2):114\u2013122","journal-title":"Eur Urol"},{"key":"6742_CR5","doi-asserted-by":"crossref","unstructured":"Powles T, Kann AG, Castellano D, Gross-Goupil M, Nishiyama H, Bracarda S, Bjerggaard Jensen J, Makaroff L, Jiang S, Ku JH, Park SH (2025) ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer. N Engl J Med. Oct 20","DOI":"10.1056\/NEJMoa2511885"},{"issue":"2","key":"6742_CR6","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41571-025-01095-x","volume":"23","author":"S Coca Membribes","year":"2026","unstructured":"Coca Membribes S, Szabados B, Powles T (2026) Towards biomarker-driven therapies for urothelial carcinoma. Nat Reviews Clin Oncol 23(2):92\u2013106","journal-title":"Nat Reviews Clin Oncol"},{"issue":"1","key":"6742_CR7","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/his.70047","volume":"88","author":"CF Harrs","year":"2026","unstructured":"Harrs CF, Pusala S, Cheng L, Jazayeri B, Li R (2026) Recent advances in liquid biopsy for genitourinary cancers: A narrative review. Histopathology 88(1):338\u2013352","journal-title":"Histopathology"},{"key":"6742_CR8","doi-asserted-by":"crossref","unstructured":"Mellema JJ, Stockem CF, Herberts C, Cheung SK, Vis DJ, van Rhijn BW, Mertens LS, Boellaard TN, van Montfoort ML, Balduzzi S, de Feijter JM Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial. Nat Med 2026 Feb 27:1\u20138","DOI":"10.1038\/s41591-026-04271-3"},{"issue":"3","key":"6742_CR9","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/JU.0000000000004849","volume":"215","author":"D Zhao","year":"2026","unstructured":"Zhao D, Khatri VM, Nakashima JY, Chadha J, Chatwal M, Zhang J, Ionescu F, Linscott JA, Li R, Poch M, Sexton W (2026) Early detection of metastatic progression by circulating tumor DNA in patients undergoing bladder-preserving trimodality therapy. J Urol 215(3):305\u2013315","journal-title":"J Urol"},{"key":"6742_CR10","doi-asserted-by":"crossref","unstructured":"Ito K, Braun DA (2026) Next-generation liquid biopsies: detecting circulating epigenetic changes to identify translocation renal cell carcinoma. J Clin Investig. ;136(3)","DOI":"10.1172\/JCI201599"},{"issue":"9","key":"6742_CR11","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/s41585-025-01023-9","volume":"22","author":"SV Lindskrog","year":"2025","unstructured":"Lindskrog SV, Strandgaard T, Nordentoft I, Galsky MD, Powles T, Agerb\u00e6k M, Jensen JB, Alix-Panabi\u00e8res C, Dyrskj\u00f8t L (2025) Circulating tumour DNA and circulating tumour cells in bladder cancer\u2014from discovery to clinical implementation. Nat Reviews Urol 22(9):590\u2013608","journal-title":"Nat Reviews Urol"},{"key":"6742_CR12","doi-asserted-by":"crossref","unstructured":"Zheng J, Qin C, Wang Q, Tian D, Chen Z (2024) Circulating tumour DNA-Based molecular residual disease detection in resectable cancers: a systematic review and meta-analysis. EBioMedicine. ;103","DOI":"10.1016\/j.ebiom.2024.105109"},{"issue":"9","key":"6742_CR13","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.ccell.2024.08.013","volume":"42","author":"J Xu","year":"2024","unstructured":"Xu J, Wan R, Cai Y, Cai S, Wu L, Li B, Duan J, Cheng Y, Li X, Wang X, Han L (2024) Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancer. Cancer Cell 42(9):1598\u20131613","journal-title":"Cancer Cell"},{"key":"6742_CR14","doi-asserted-by":"publisher","first-page":"1483454","DOI":"10.3389\/fonc.2024.1483454","volume":"14","author":"X Yin","year":"2024","unstructured":"Yin X, Song Y, Deng W, Blake N, Luo X, Meng J (2024) Potential predictive biomarkers in antitumor immunotherapy: navigating the future of antitumor treatment and immune checkpoint inhibitor efficacy. Front Oncol 14:1483454","journal-title":"Front Oncol"},{"key":"6742_CR15","doi-asserted-by":"publisher","first-page":"114159","DOI":"10.1016\/j.ejca.2024.114159","volume":"207","author":"N Verschoor","year":"2024","unstructured":"Verschoor N, Bos MK, Oomen-de Hoop E, Martens JW, Sleijfer S, Jager A, Beije N (2024) A review of trials investigating ctDNA-guided adjuvant treatment of solid tumors: The importance of trial design. Eur J Cancer 207:114159","journal-title":"Eur J Cancer"},{"issue":"6","key":"6742_CR16","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.eururo.2015.07.039","volume":"68","author":"JP Sfakianos","year":"2015","unstructured":"Sfakianos JP, Cha EK, Iyer G, Scott SN, Zabor EC, Shah RH, Ren Q, Bagrodia A, Kim PH, Hakimi AA, Ostrovnaya I, Ramirez R, Hanrahan AJ, Desai NB, Sun A, Pinciroli P, Rosenberg JE, Dalbagni G, Schultz N, Bajorin DF, Reuter VE, Berger MF, Bochner BH, Al-Ahmadie HA, Solit DB, Coleman JA (2015) Genomic characterization of upper tract urothelial carcinoma. Eur Urol 68(6):970\u2013977","journal-title":"Eur Urol"},{"issue":"2","key":"6742_CR17","doi-asserted-by":"publisher","first-page":"e471912","DOI":"10.1200\/EDBK-25-471912","volume":"45","author":"J Bellmunt","year":"2025","unstructured":"Bellmunt J, Russell BM, Szabados B, Valderrama BP, Nadal R (2025) Current and future role of circulating DNA in the diagnosis and management of urothelial carcinoma. Am Soc Clin Oncol Educational Book 45(2):e471912","journal-title":"Am Soc Clin Oncol Educational Book"},{"key":"6742_CR18","doi-asserted-by":"crossref","unstructured":"Johnson DB, Nassar AH, Aijaz A, Knight A, Zerey MM, Rini BI, Naqash AR, Sullivan RJ Reconsidering adjuvant and perioperative immune-checkpoint inhibition: de-escalation, expansion and personalization. Nat Reviews Clin Oncol 2026 Feb 18:1\u20135","DOI":"10.1038\/s41571-026-01123-4"},{"key":"6742_CR19","doi-asserted-by":"crossref","unstructured":"Gupta S, Li R, Hensley PJ, Daneshmand S, Faltas BM, Grivas P, Lobo N, Mir MC, Meeks JJ, Mouw KW, Moschini M (2026) Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group. European urology. Feb 21","DOI":"10.1016\/j.eururo.2026.01.029"},{"issue":"3","key":"6742_CR20","doi-asserted-by":"publisher","first-page":"e516902","DOI":"10.1200\/EDBK-26-516902","volume":"46","author":"RR McKay","year":"2026","unstructured":"McKay RR, Tipirneni A, Bangs R, Guercio BJ (2026) Neoadjuvant Systemic Therapy in Kidney and Bladder Cancer: Current Evidence and Emerging Paradigms. Am Soc Clin Oncol Educational Book 46(3):e516902","journal-title":"Am Soc Clin Oncol Educational Book"},{"issue":"3","key":"6742_CR21","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41571-025-01113-y","volume":"23","author":"BB Suelmann","year":"2026","unstructured":"Suelmann BB, van der Heijden MS (2026) From detection to direction: ctDNA-guided personalized therapy for muscle-invasive bladder cancer: Urological cancer. Nat Reviews Clin Oncol 23(3):155\u2013156","journal-title":"Nat Reviews Clin Oncol"},{"key":"6742_CR22","doi-asserted-by":"crossref","unstructured":"Zhang T, Gao Z, Xiao S, Zou X, Huang X, Zeng D, Li J, Wang Y (2026 May) Precision Medicine in Bladder Cancer: Redefining Treatment Paradigms Through ADCs, Immunotherapy, and Molecular Subtyping. Crit Rev Oncol\/Hematol 1:105348","DOI":"10.1016\/j.critrevonc.2026.105348"},{"key":"6742_CR23","doi-asserted-by":"publisher","first-page":"1767712","DOI":"10.3389\/fonc.2026.1767712","volume":"16","author":"JB Aragon-Ching","year":"2026","unstructured":"Aragon-Ching JB, Urabe F, Yajima S (2026) Circulating tumor DNA as a prognostic and monitoring biomarker in urothelial cancers. Front Oncol 16:1767712","journal-title":"Front Oncol"},{"issue":"1","key":"6742_CR24","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","volume":"85","author":"JA Witjes","year":"2024","unstructured":"Witjes JA, Bruins HM, Carri\u00f3n A, Cathomas R, Comp\u00e9rat E, Efstathiou JA, Fietkau R, Gakis G, Lorch A, Martini A, Mertens LS (2024) European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines. Eur Urol 85(1):17\u201331","journal-title":"Eur Urol"},{"issue":"5","key":"6742_CR25","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","volume":"87","author":"AG van der Heijden","year":"2025","unstructured":"van der Heijden AG, Bruins HM, Carrion A, Cathomas R, Comp\u00e9rat E, Dimitropoulos K, Efstathiou JA, Fietkau R, Kailavasan M, Lorch A, Martini A (2025) European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2025 guidelines. Eur Urol 87(5):582\u2013600","journal-title":"Eur Urol"},{"issue":"3","key":"6742_CR26","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","volume":"33","author":"T Powles","year":"2022","unstructured":"Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, Necchi A, Valderrama BP, Ravaud A, Shariat SF, Szabados B (2022) Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 33(3):244\u2013258","journal-title":"Ann Oncol"},{"issue":"25","key":"6742_CR27","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1200\/JCO.21.02660","volume":"40","author":"M Provencio","year":"2022","unstructured":"Provencio M, Serna-Blasco R, Nadal E, Insa A, Garc\u00eda-Campelo MR, Casal Rubio J, D\u00f3mine M, Majem M, Rodr\u00edguez-Abreu D, Mart\u00ednez-Mart\u00ed A, De Castro Carpeno J (2022) Overall survival and biomarker analysis of neoadjuvant nivolumab plus chemotherapy in operable stage IIIA non\u2013small-cell lung cancer (NADIM phase II trial). J Clin Oncol 40(25):2924\u20132933","journal-title":"J Clin Oncol"},{"issue":"1","key":"6742_CR28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1200\/JCO.24.00340","volume":"43","author":"MD Galsky","year":"2025","unstructured":"Galsky MD, Witjes JA, Gschwend JE, Milowsky MI, Schenker M, Valderrama BP, Tomita Y, Bamias A, Lebret T, Shariat SF, Park SH (2025) Adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma: expanded efficacy from CheckMate 274. J Clin Oncol 43(1):15\u201321","journal-title":"J Clin Oncol"},{"issue":"6","key":"6742_CR29","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1097\/JU.0000000000003480","volume":"209","author":"JA Coleman","year":"2023","unstructured":"Coleman JA, Clark PE, Bixler BR, Buckley DI, Chang SS, Chou R, Hoffman-Censits J, Kulkarni GS, Matin SF, Pierorazio PM, Potretzke AM (2023) Diagnosis and management of non-metastatic upper tract urothelial carcinoma: AUA\/SUO guideline. J Urol 209(6):1071\u20131081","journal-title":"J Urol"},{"issue":"2","key":"6742_CR30","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S1470-2045(23)00587-9","volume":"25","author":"C Pfister","year":"2024","unstructured":"Pfister C, Gravis G, Flechon A, Chevreau C, Mahammedi H, Laguerre B, Guillot A, Joly F, Soulie M, Allory Y, Harter V (2024) Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study. Lancet Oncol 25(2):255\u2013264","journal-title":"Lancet Oncol"},{"issue":"10379","key":"6742_CR31","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/S0140-6736(22)02574-0","volume":"401","author":"RJ Motzer","year":"2023","unstructured":"Motzer RJ, Russo P, Gr\u00fcnwald V, Tomita Y, Zurawski B, Parikh O, Buti S, Barth\u00e9l\u00e9my P, Goh JC, Ye D, Lingua A (2023) Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial. Lancet 401(10379):821\u2013832","journal-title":"Lancet"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06742-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-026-06742-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06742-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T17:54:33Z","timestamp":1787853273000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-026-06742-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6742"],"URL":"https:\/\/doi.org\/10.1007\/s00345-026-06742-1","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"assertion":[{"value":"9 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study was a systematic review and meta-analysis of previously published studies and did not involve the direct recruitment of human participants or access to identifiable patient-level data.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"610"}}